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Calcium signalling links MYC to NUAK1
T Monteverde1, J Tait-Mulder1, A Hedley2, JR Knight2, OJ Sansom1,2 and DJ Murphy1,2
NUAK1 is a member of the AMPK-related family of kinases. Recent evidence suggests that NUAK1 is an important regulator of cell
adhesion and migration, cellular and organismal metabolism, and regulation of TAU stability. As such, NUAK1 may play key roles in
multiple diseases ranging from neurodegeneration to diabetes and metastatic cancer. Previous work revealed a crucial role for
NUAK1 in supporting viability of tumour cells speciﬁcally when MYC is overexpressed. This role is surprising, given that NUAK1 is
activated by the tumour suppressor LKB1. Here we show that, in tumour cells lacking LKB1, NUAK1 activity is maintained by an
alternative pathway involving calcium-dependent activation of PKCα. Calcium/PKCα-dependent activation of NUAK1 supports
engagement of the AMPK-TORC1 metabolic checkpoint, thereby protecting tumour cells from MYC-driven cell death, and indeed,
MYC selects for this pathway in part via transcriptional regulation of PKCα and ITPR. Our data point to a novel role for calcium in
supporting tumour cell viability and clarify the synthetic lethal interaction between NUAK1 and MYC.
Oncogene advance online publication, 6 November 2017; doi:10.1038/onc.2017.394
INTRODUCTION
NUAK1, also known as ARK5, is one of 12 kinases related by
sequence homology to the catalytic α-subunits of the metabolic
regulator AMPK.1 Perturbation of NUAK1 has revealed a diverse
array of phenotypes, pointing to roles for NUAK1 in regulating cell
adhesion,2 directional migration,3,4 neuronal axon branching,5
glycogen synthesis,6 replicative senescence7 and TAU
stabilization.8 Overexpression of NUAK1 is associated with poor
prognosis in multiple cancers, including colorectal,9 (Port, et al.,
personal communication) ovarian,10–12 and lung,13 among
others.14 Accordingly, NUAK1 is a common target of multiple
miRNAs that are frequently lost during progression to metastatic
disease.15–20 Despite the evidence that NUAK1 may contribute to
multiple diseases, the signal transduction context of NUAK1
remains poorly deﬁned.
We previously identiﬁed a role for NUAK1 in supporting viability
of cancer cells when MYC is overexpressed.21 Brieﬂy, we showed
that MYC-overexpressing cells are unable to maintain energetic
homoeostasis in the absence of NUAK1, in part due to a failure to
efﬁciently activate AMPK and slow TORC1-dependent protein
translation when faced with metabolic stress. NUAK1 and AMPK
thus protect cancer cells from metabolic stress, which is a hallmark
of most solid tumours.22,23 This tumour-promoting activity of NUAK1
and AMPK is somewhat paradoxical, given that both are activated
by LKB1, an established tumour suppressor: LKB1 phosphorylates
AMPKα subunits on Thr172, and NUAK1 on Thr211, within the
conserved T-loop of the kinase domain.1,24 Notably, AMPKαT172 is
phosphorylated by CamKK2 in response to calcium signalling,25,26
suggesting that the T-loops of these kinases may be accessible to
other upstream regulators in addition to LKB1.
Here we demonstrate that NUAK1, like AMPK, is active in cancer
cells in the absence of LKB1. Similar to AMPK, basal NUAK1 activity
is maintained by tonic Ca2+ signalling and activity increases in
response to Ca2+ mobilization. Unlike AMPK, NUAK1 does not
appear to be regulated by CamKK2, but rather by Ca2+-dependent
activation of PKCα. Signiﬁcantly, suppression of either NUAK1 or
PKCα leads to MYC-dependent cell death and MYC selects for
increased Ca2+ signalling in part via transcriptional regulation of
Ca2+-dependent protein kinases. Our work thus reveals a novel
role for Ca2+ signalling in supporting viability of MYC-
overexpressing cells via activation of PKCα and NUAK1.
RESULTS
NUAK1 is speciﬁcally required for Ca2+-dependent AMPK activity
Depletion of NUAK1 impairs activation of AMPK in response to
sustained MYC deregulation.21 We asked whether this require-
ment for NUAK1 is a general feature of AMPK regulation or rather
a context-dependent event. AMPK is activated by phosphorylation
of the α-subunit on Thr172 by LKB1, and activity is further
enhanced upon a drop in the ATP:AMP/ADP ratio.27 Alternatively,
CamKK2 can phosphorylate AMPKα Thr172 in response to calcium
signalling.25 Additionally, AMPK can be activated upon direct
binding of pharmacological agonists, such as salicylate or
A769662.28 We therefore considered three modes of AMPK
activation: indirect activation in response to energetic stress,
direct activation by agonist binding and calcium-dependent
activation.
In order to investigate the requirement of each mode of AMPK
activation for NUAK1, we made use of a recently described highly
selective NUAK1 kinase inhibitor, HTH-01-015. This molecule
shows little-to-no activity towards AMPK, NUAK2 or other AMPK-
related kinases (ARKs) in vitro.29 Treatment of U2OS cells with
HTH-01-015 for 1 h, 6 h or overnight reduced Ser445 phosphoryla-
tion of the NUAK1 substrate MYPT1 in a dose-dependent manner
(Figure 1a). In contrast, acute treatment with HTH-01-015 had no
effect on basal Ser79 phosphorylation of the canonical AMPK
substrate, ACC. Acute activation of AMPK in U2OS cells using the
direct agonist A769662, the electron transport chain inhibitor
phenformin or the widely-used Ca2+ ionophore A23187, all
increased phospho-ACC levels. Co-treatment with HTH-01-015
attenuated this increase in response to AMPK activation by Ca2+
and by phenformin, but not by the direct AMPK agonist A769662,
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indicating that the requirement for NUAK1 during AMPK
activation is context dependent (Figure 1b).
Suppression of Ca2+-dependent AMPK activity by HTH-01-015
suggested that NUAK1 may be important during LKB1-
independent regulation of AMPK. We therefore repeated the
above analysis in HeLa cells, which lack functional LKB1
(Figure 1c). As measured by ACC phosphorylation, activation of
AMPK by either direct agonist or phenformin was much weaker in
HeLa cells than in U2OS cells, and neither was affected by NUAK1
inhibition. In contrast, Ca2+ ionophore clearly increased AMPK
activity and this increase was attenuated by NUAK1 inhibition
(Figure 1d), suggesting a speciﬁc role for NUAK1 in this mode of
AMPK activation.
NUAK1 is activated by calcium signalling
LKB1 is a master regulator of the AMPK-related kinases, including
NUAK1.1 Our results in HeLa cells implied that NUAK1 is active in
these cells despite the absence of LKB1. The myosin phosphatase
targeting subunit of PP1β, MYPT1 (PPP1R12A), is to date the best-
characterized substrate of NUAK1 kinase activity.2 Acute treatment
of HeLa cells with HTH-01-015 reduced MYPT1 phospho-Ser445
levels, suggesting that NUAK1 is indeed catalytically active in
these cells (Figure 2a). Depletion of NUAK1 using two indepen-
dent siRNAs also reduced phospho-MYPT1S445, conﬁrming the
speciﬁcity of the inhibitor effect (Figure 2b). The partial reduction
in phospho-MYPT1S445 observed upon NUAK1 suppression
suggested that other kinases may contribute to MYPT1S445
phosphorylation. Indeed, NUAK2, the ARK most closely related
to NUAK1, was previously reported to phosphorylate this site.2
Accordingly, depletion of NUAK2 also reduced phospho-
MYPT1S445 levels, while combined suppression of both NUAK1
and 2 almost completely abolished MYPT1S445 phosphorylation
(Figure 2c). Pharmacological inhibition of both NUAK1 and NUAK2,
using the dual-speciﬁcity inhibitor WZ400329 similarly abolished
MYPT1 phosphorylation, corroborating the results of the siRNA
(Supplementary Figure S1A). Thus, both NUAK1 and NUAK2 are
active in HeLa cells despite their LKB1-null status.
These data indicate that NUAK1 is activated in HeLa cells by an
alternative upstream kinase. We ﬁrst asked if CamKK2, a known
upstream activator of AMPK, might similarly activate NUAK1.
Treatment of HeLa cells with the CamKK2 inhibitor STO-609
strongly suppressed phosphorylation of both AMPKαT172 and
ACCS79 but had no inﬂuence on phospho-MYPT1S445 levels
(Figure 2d), suggesting that CamKK2 is not upstream of NUAK1.
Strikingly, treatment with calcium ionophore A23187 increased
phosphorylation of both ACCS79 and MYPT1S445 and co-treatment
with STO-609 reduced ACCS79 phosphorylation but again had no
effect on phospho-MYPT1S445, suggesting that NUAK1 is activated
by a calcium-dependent kinase other than CamKK2. Accordingly,
treatment of HeLa cells with two different Ca2+ ionophores,
p-ACCS79
ACC
β-Actin
250
250
40
HTH-01-015
PhenA769662A23187
+ + ++
U2OS
le
ve
l [a
.u.
] p-ACCS79
- - - -
0
2
4
6
HeLa
p-ACCS79
ACC
β-Actin
p-ACCS79
le
ve
l [a
.u.
]
HTH-01-015+ + ++- - - -
250
250
40
0
2
4
6
PhenA769662A23187
LKB1
β-Actin
55
40
U2OSHeLa
β-Actin
40
0 3 5 10 μM HTH-01-015
p-MYPT1S445
MYPT1
130
130
p-ACCS79
ACC250
250
1 hr treatment
p-MYPT1S445
MYPT1
β-Actin50
130
130
6 hrs treatment
p-MYPT1S445
MYPT1
β-Actin50
130
130
16 hrs treatment
Figure 1. NUAK1 is required for calcium-dependent activation of AMPK. (a) Whole-cell extracts from U2OS cells treated with the indicated
concentrations of HTH-01-015 for 1, 6 or 16 h and probed with the indicated antibodies. (b) Lysates from U2OS cells pre-treated with HTH-01-
015 for 1 h prior to stimulation with 3 μM A23187 (10 min), 100 μM A769662 (1 h) or 10 mM Phenformin (1 h) and blotted for phospho- and total
ACC. Densitometry shows p-ACC levels in the image shown. (c) Lysates from equal numbers of U2OS and HeLa cells were probed for LKB1.
Images are from the same gel and immunoblot, but rearranged to omit extraneous data. (d) Lysates from HeLa cells pre-treated with HTH-01-
015 for 1 h prior to stimulation with 3 μM A23187 (10 min), 100 μM A769662 (1 h) or 10 mM Phenformin (1 h) and blotted for phospho- and total
ACC. Densitometry shows p-ACC levels in the image shown. All images are representative of at least three independent experiments.
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Ionomycin or A23187, increased MYPT1S445 phosphorylation and
this increase was attenuated by NUAK1 inhibition (Figure 2e).
Conversely, treatment with the calcium chelator BAPTA strongly
reduced basal levels of phospho-MYPT1S445 (Figure 2f). Collec-
tively, these data suggest that Ca2+ signalling activates NUAK1 in
the absence of LKB1. Interestingly, treatment with the Ca2+
ionophore A23187 could partially rescue MYPT1S445 phosphoryla-
tion in the presence of NUAK1 inhibitor but not in the presence of
the dual NUAK1/NUAK2 inhibitor, WZ4003 (Supplementary
Figure S1A). A23187 also partially rescued MYPT1S445
phosphorylation upon suppression of either NUAK1 or NUAK2
but not both (Supplementary Figure S1B), together suggesting
that NUAK2 is also activated by calcium signalling in the absence
of LKB1.
MYC drives increased PKC activity
Calcium regulates multiple kinases including Ca2+/Calmodulin-
dependent kinases 1–4; CamKK1 and 2; and conventional isoforms
of protein kinase C (cPKC). Noting our previously described link
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Figure 2. Calcium signalling activates NUAK1. (a) Lysates from HeLa cells treated with the indicated concentrations of HTH-01-015 for 1 h and
probed for phospho- and total MYPT1. (b) Lysates from HeLa cells transfected with NUAK1 siRNA and probed with the indicated antibodies.
nt, non-targeting control siRNA. (c) Lysates from HeLa cells transfected with NUAK2 (+) or control (− ) siRNA and treated ±10 μM HTH-01-015, as
indicated. Densitometry shows phospho-MYPT1 levels from the image shown. (d) Lysates from HeLa cells pre-treated with 5 μg/ml STO-609
for 1 h prior to stimulation with 3 μM A23187 (10 min) as indicated, and probed with the indicated antibodies. (e) Lysates from HeLa cells pre-
treated with 10 μM HTH-01-015 for 1 h prior to stimulation with 3 μM A23187 or Ionomycin (both 10 min) as indicated, and probed for
phosphor-MYPT1. (f) Lysates from HeLa cells treated ± 20 μM BAPTA for 30 min. All images are representative of at least three independent
experiments, except (f) where N= 2.
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between NUAK1 and MYC overexpression, we wondered if MYC
might drive expression of a calcium-dependent kinase upstream
of NUAK1. Oncogenic transformation of mouse embryo ﬁbroblasts
(MEFs) with MYC speciﬁcally increased expression of PKCα and
CamKKβ, along with the inositol tri-phosphate receptor ITPR1,
which regulates calcium release from the endoplasmic reticulum
(Figure 3a). Notably, MYC was previously shown to bind the
promoters of all three genes in diverse cell types, including
MEFs.30 MYC overexpression strongly enhanced PKC activity, as
measured by phosphorylation of the canonical PKC substrate
MARCKS,31 and modestly but reproducibly enhanced Ca2+-depen-
dent activation of AMPK (Figures 3b and c). MARCKS phosphor-
ylation was suppressed by BAPTA or by treatment with the PKCα/β
inhibitor Gö6976,32 suggesting that deregulated MYC speciﬁcally
increases activity of Ca2+-dependent PKC isoforms (Figure 3b).
HeLa cells express high levels of MYC33 and depletion of MYC in
HeLa cells reduced p-MARCKS levels (Figure 3d), suggesting that
this consequence of MYC overexpression is conserved across
species.
NUAK1 is activated by PKCα
We next asked if targeted suppression of PKC impairs NUAK1
activity. Inhibition of PKCα and β isoforms with Gö6976 strongly
reduced p-MYPT1S445 in a dose-dependent manner (Figure 4a).
Notably, this effect was transient, as p-MYPT1S445 levels rebounded
within 16 h of Gö6976 treatment, and this was mirrored by a
recovery in overall PKC activity (Figure 4b). SiRNA-mediated
depletion of PKCα also reduced p-MYPT1S445 levels to a degree
that was similar to NUAK1 inhibition but less than that observed
after 1 h treatment with the highest concentration of Gö6976 tested,
which may reﬂect promiscuity of the PKC inhibitor at this dose
(Figure 4c; note that a lower concentration of Gö6976, 0.5 μM, was
used for all subsequent experiments). No effect on p-MYPT1S445 was
observed using siRNA targeting PKCβ1 (not shown).
In light of our data showing that both NUAK1 and NUAK2
contribute to Ca2+- induced MYPT1S445 phosphorylation, we asked
if the effects of PKCα depletion were mediated by either NUAK1,
NUAK2, or both. The reduction of p-MYPT1S445 achieved upon
NUAK1 depletion was minimally inﬂuenced by co-depletion of
PKCα (compare lane 2 with lane 4), consistent with a role for PKCα
upstream of NUAK1. In contrast, suppression of MYPT1S445
phosphorylation by NUAK2 depletion was strongly enhanced by
co-depletion of PKCα (compare lanes 5 and 6), suggesting that
NUAK2 resides in a distinct pathway (Figure 4d). Interestingly,
depletion of PKCα consistently reduced expression of NUAK1
(Figure 4d). This effect was observed using two independent
siRNAs targeting PKCα and neither siRNA inﬂuenced NUAK1
mRNA levels (Supplementary Figure S2), strongly suggesting that
the effect does not reﬂect off-target activity of the siRNAs used.
Proteasome inhibition largely rescued NUAK1 levels upon deple-
tion of PKCα, suggesting that PKCα promotes NUAK1 protein
stability (Supplementary Figures S2B and C).
To examine the effects of acute calcium signalling on NUAK1
activation, we requisitioned an afﬁnity-puriﬁed phosphopeptide
antibody against T211-phosphorylated NUAK1, and overexpressed
either wild type or T211A mutant, FLAG-tagged, NUAK1 in HeLa
cells. In FLAG immunoprecipitates, the antibody strongly detected
a band migrating at the correct size for NUAK1 only in lysates from
WT but not from T211A mutant-overexpressing cells. Identical
results were obtained using a commercial anti-phospho-
AMPKαT172 antibody that cross-reacts with overexpressed
phospho-NUAK1T21134 (Supplementary Figure S2). For both anti-
bodies, the intensity of this band increased within 10 min of Ca2+
ionophore treatment and decreased upon acute treatment with
PKC inhibitor (Figure 4e and Supplementary Figure S2).
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Figure 3. MYC selects for increased calcium signalling. (a) Total RNA isolated from WT or Rosa26-lsl-MYC MEFs harvested 24 h after infection
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Figure 4. PKCα mediates calcium-dependent NUAK1 activation. (a) Lysates from HeLa cells treated with the indicated concentrations of
Gö6976 for 1 h and probed with the indicated antibodies. (b) Lysates from HeLa cells treated with 1 μM Gö6976 or 10 μM HTH-01-015 for 1 or
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PKCα and/or NUAK2 or NUAK1, probed with the indicated antibodies. Arrowhead indicates the correct band for NUAK2. (e) Anti-FLAG
immunoprecipitates from HeLa cells transfected with FLAG-tagged WT or T211A mutant NUAK1, treated with 0.5 μM Gö6976 and/or 3 μM
A23187, and probed with anti-phospho-NUAK1T211 antibody. (f) Lysates from HeLa cells pre-treated with 0.5 μM Gö6976 for 1 h prior to
stimulation with 3 μM A23187, as per (e) and probed for phosphor-MYPT1S445. All images are representative of at least three independent
experiments, except (e) where N= 2.
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Examination of p-MYPT1S445 under the same conditions showed
similar responses to Ca2+ ionophore and PKC inhibitor treatment
with one important difference: whereas Ca2+ ionophore could
partially rescue the effect of Gö6976 on MYPT1S445 phosphoryla-
tion (Figure 4f), no such rescue was evident in p-NUAK1T211 levels.
Taken with the data above, these data suggest that Ca2+ signalling
regulates NUAK1 in HeLa cells via activation of PKCα, while
MYPT1S445 phosphorylation is regulated both via NUAK1 and via a
distinct pathway involving Ca2+-dependent, Gö6976-refractory,
activation of NUAK2.
The PKCα–NUAK1 pathway supports viability of
MYC-overexpressing cells
We previously showed that MYC-overexpressing cells require
NUAK1 to sustain viability.21 HeLa cells express high levels of MYC
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and prolonged treatment (2 days) with 10 μM HTH-01-015 resulted
in pronounced HeLa cell apoptosis (Figure 5a). Partial inhibition of
NUAK1 with 5 μM HTH-01-015 was surprisingly well tolerated,
suggesting that a threshold level of NUAK1 activity is sufﬁcient to
prevent cell death. Similar results were obtained using siRNA-
mediated NUAK1 depletion, in that death was only induced upon
very strong suppression of NUAK1 expression (Figure 5b). Death
induced by 10 μM HTH-01-015 was signiﬁcantly attenuated by
reducing MYC levels with either of two MYC-targeting shRNAs
(Figure 5c), consistent with our previous demonstration of MYC
‘dose-dependence’ for the synthetic lethal interaction with
NUAK1.21 Consistent with a role for PKCα upstream of NUAK1,
depletion of PKCα with either of two siRNAs also drove
pronounced HeLa cell apoptosis (Figure 5d), while treatment of
HeLa cells with Gö6976 signiﬁcantly enhanced killing by a
sublethal dose of NUAK1 inhibitor (Figure 5e). Note that Gö6976
treatment alone did not kill HeLa cells, likely owing to the
transient nature of PKC inhibition by this compound (Figure 4b).
We asked if death induced upon loss of PKCα mechanistically
mirrored that induced by loss of NUAK1. Under conditions of
energetic stress, cancer cells activate a metabolic checkpoint in
order to limit mTORC1-driven macromolecular synthesis, via
phosphorylation of RAPTOR-Ser792 by AMPK.35 Failure to engage
this checkpoint results in death of stressed cells24,36 and our
previous work showed that NUAK1 is required for efﬁcient
checkpoint activation.21 Dynamic analysis of this checkpoint in
HeLa cells revealed a complex response to Ca2+ ionophore, with
p-RAPTORS792 increasing steadily over time whereas phospho-
S6KT389 and phospho-4EBP1T37/46 levels, downstream of mTORC1,
rose initially before declining (Figure 5f), consistent with Ca2+
simultaneously activating the mTORC1 pathway as well as the
inhibitory AMPK–Raptor pathway.37 Importantly, depletion of
either PKCα or NUAK1 reduced both basal and Ca2+-activated
phosphorylation of RAPTOR-Ser792, suggesting that failure to
efﬁciently engage the metabolic checkpoint may contribute to
death in both instances (Figure 5g). Consistent with this
hypothesis, treatment of HeLa cells with the mTORC1 inhibitor
Rapamycin signiﬁcantly rescued cells from death induced by
depletion of either NUAK1 or PKCα, and the degree of rescue was
similar in both instances (Figure 5h). Although these data do
suggest that other downstream pathways likely contribute to cell
death, they strongly support the core observation that NUAK1 and
PKCα act in a similar manner to support cell viability.
NUAK1 regulates RAPTOR via both AMPK-dependent and
independent mechanisms
Conﬁrming the requirement for NUAK1 to restrain mTORC1
activity, S35-Methionine labelling showed increased protein
translation in NUAK1-depleted HeLa and U2OS cells (Figure 6a),
as shown previously.21 We therefore examined RAPTOR regulation
by NUAK1 in greater detail. Activation of AMPK by Ca2+ ionophore
(A23187), phenformin or salicylate in U2OS cells all lead to
increased RAPTORS792 phosphorylation. In contrast with the
selective requirement for NUAK1 during AMPK regulation of
ACC, RAPTORS792 phosphorylation was reduced by NUAK1
inhibition under all conditions examined (Figure 6b). Depletion
of NUAK1 also signiﬁcantly reduced both basal and AMPK-
activated RAPTORS792 phosphorylation, conﬁrming the speciﬁcity
of this effect (Figure 6c). Inhibition of NUAK1 reduced AMPK-
dependent RAPTORS792 phosphorylation in immortalized
Prkaa1FL/FL;Prkaa2FL/FL double ﬂoxed MEFs. Strikingly, phospho-
RAPTORS792 was still detectable in the same MEFs after CRE
recombinase-mediated deletion of AMPKα1 and α2, albeit at
reduced levels, and NUAK1 inhibition further reduced detection,
indicating that NUAK1 can regulate RAPTOR in the absence of
functional AMPK (Figure 6d). Accordingly, deletion of NUAK1 in
Nuak1FL/FL MEFs also reduced both basal and AMPK-activated
RAPTORS792 phosphorylation (Figure 6e). Together these data
show that efﬁcient restraint of mTORC1 via inhibitory phosphor-
ylation of RAPTOR requires both NUAK1 and AMPK.
DISCUSSION
Suppression of NUAK1 is synthetic lethal with MYC overexpres-
sion, suggesting that NUAK1 may present an attractive target for
treatment of MYC-driven cancers.21,38 A thorough understanding
of the signal transduction context of NUAK1 will be crucial to
determine if such a strategy is feasible in human subjects. Here we
show that NUAK1 is active in HeLa cells despite the absence of
LKB1. We show modulation of NUAK1 activity by calcium
perturbation, and present evidence that PKCα participates in
NUAK1 activation in response to Ca2+ signalling. Importantly,
Ca2+-dependent activation of the AMPK–mTORC1 metabolic
checkpoint requires both PKCα and NUAK1, and depletion of
either drives pronounced apoptosis, suggesting a positive role for
this pathway in tumour maintenance. Our speciﬁc ﬁndings are
summarized in Figure 7.
It is widely thought that the tumour suppressive function of
LKB1 is mediated by one or more of the AMPK-family kinases.27,39
Loss of LKB1 would thus be predicted to result in loss of ARK
activity, downstream. Accordingly, deletion of Stk11, encoding
Lkb1, in wild-type MEFs was shown to suppress activity of AMPK
and all related ARKs, as measured in cell-free kinase assays using a
peptide substrate optimized for AMPK.1 However, several of the
ARKs, including Nuak1, showed only weak activity towards the
peptide used, suggesting it was a suboptimal substrate for these
kinases. Indeed, subtle differences in peptide substrate sequences
have revealed distinct preferential phosphorylation patterns of
AMPK and MARK kinases.40 Thus, in vitro kinase assays with a one-
size-ﬁts-all peptide substrate likely fail to accurately reﬂect
Figure 5. The PKCa–NUAK1 pathway supports viability of MYC-overexpressing cells. (a) Apoptosis induced in HeLa cells by the indicated doses
of HTH-01-015, measured by FACS analysis of cells stained with Annexin V and propidium iodide (AV/PI) 48 h post-treatment: Red bars denote
AV single-positive cells while black bars denote AV/PI double-positive cells (for a–e, h). Mean and s.d. of three independent experiments
shown (a, b, d, e, h). Statistical signiﬁcance was determined by one-way ANOVA, Tukey’s multiple comparison test (a–e). The immunoblot
shows suppression of MYPT1 phosphorylation after 1 h treatment. (b) Apoptosis in HeLa cells induced by NUAK1 siRNA, measured 3 days
post-transfection. Immunoblot shows NUAK1 and p-MYPT1 levels at 24 h. nt, non-targeting control siRNA. (c) Apoptosis induced by 10 μM
HTH-01-015 in HeLa cells transfected with MYC shRNA where indicated. Mean and s.d. of technical triplicates from a representative (median)
experiment shown due to wide inter-experimental variation in efﬁciency of MYC depletion. N= 5. (d) Apoptosis induced in HeLa cells by PKCα
siRNA, measured 3 days post-transfection. Immunoblot shows PKCα levels after 24 h. nt, non-targeting control siRNA. (e) Apoptosis induced in
HeLa cells after treatment with 5 μM HTH-01-015±0.5 μM Gö6976 for 48 h. Immunoblot shows p-MYPT1S445 levels after 1 h drug treatment.
(f) Dynamic response of the AMPK–mTORC1 pathway to calcium mobilization. HeLa cells were harvested at 0, 1, 2 and 4 h post-treatment with
3 μM A23187 and probed with the indicated antibodies. The graphs show densitometric measurements of p-RAPTORS792, p-S6KT389 and
p-4EBP1T37/46 from the blots shown, normalized to Actin. N= 2. (g) Lysates from HeLa cells transfected with NUAK1, PKCα or non-targeting (− )
siRNA for 24 h and stimulated with 3 μM A23187 for 10 min, as indicated, probed with the indicated antibodies. N= 2. (h) Apoptosis induced by
depletion of either NUAK1 or PKCα in cells treated for 48 h with 100 nM Rapamycin (Rapa) or DMSO vehicle control (− ), measured by AV/PI
FACS. Two-way ANOVA, Sidak’s multiple comparison test.
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physiological ARK activity in cells. Additionally, several indepen-
dent groups have deﬁnitively shown that AMPK is directly
phosphorylated by CamKK2, reﬂecting an alternative pathway to
AMPK activation.25,26,41,42 Activation of AMPK by CamKK2 is
particularly important in prostate cancer and in the physiological
regulation of skeletal muscle and vascular endothelial cell
function.43–45 Interestingly, the ARK SIK2 was recently shown to
be activated by an as-yet unidentiﬁed Ca2+-dependent kinase in
Ovarian cancer cells.46 Our demonstration that NUAK1 and NUAK2
are similarly regulated by Ca2+-dependent signalling thus ﬁts an
emerging pattern of calcium regulating multiple ARKs, either
alongside or in the absence of LKB1. This regulation may have
particular relevance in LKB1-deﬁcient disease settings.
Our data speak to the complexity of signal transduction through
AMPK, NUAK1 and the related ARKs. Indeed, AMPK is often
discussed as if it were a single entity. Rather, up to 12 different
permutations of trimeric AMPK complexes can assemble from the
2α, 2β and 3γ-encoded subunits, not accounting for splice
variants.22 It is likely that the different AMPK complexes may
respond differentially to distinct upstream stimuli, and indeed in
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Figure 6. NUAK1 regulates RAPTOR via AMPK-dependent and independent mechanisms. (a) Measurement of protein synthesis (methionine
incorporation) in HeLa (left panel) and U2OS (right panel) cells transfected with non-targeting (− ), NUAK1 and PKCα siRNA. Mean and s.d.
from three independent experiments shown. Statistical signiﬁcance was determined by one-tailed unpaired T-test. (b) Lysates from U2OS cells
pre-treated with 10 μM HTH-01-015 for 1 h, where indicated, prior to treatment with 6 μM A23187 (10 min), 10 mM salicylate (1 h), 10 mM
phenformin (1 h) or DMSO vehicle and blotted for phospho-S792 and total RAPTOR. N= 3. The asterisk denotes a nonspeciﬁc band in the
p-RAPTOR panel (b, c). (c) Lysates from U2OS cells transfected where indicated with siRNA targeting NUAK1 and treated with 10 mM salicylate
(1 h), 10 mM phenformin (1 h), 6 μM A23187 (10 min), 3 μM Ionomycin (10 min) or DMSO vehicle, blotted for p-RAPTORS792. N= 3. (d) Lysates
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AMPK activators in the presence or absence of 10 μM HTH-01-015, blotted with the indicated antibodies. N= 2. (e) Lysates from primary
Nuak1FL/FL MEFs stably expressing Cre-ER were treated overnight with 100 nM 4-OH-Tamoxifen (+) or vehicle control (− ) prior to stimulation as
per (d, e) with AMPK activators, then immunoblotted for p-RaptorS792. N= 2.
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terms of their activity towards speciﬁc downstream substrates. Our
demonstration of a speciﬁc requirement for NUAK1 in Ca2+
-dependent AMPK activity towards ACC, and a more general
requirement for NUAK1 in AMPK activity towards RAPTOR, point
towards a highly contextual requirement for NUAK1 and may
indicate that NUAK1 modulates the activity of a speciﬁc subset of
AMPK complexes. On top of this, the 11 related ARKs can exhibit
both overlapping and private substrate speciﬁcities. This is
reﬂected by our demonstration of an AMPK-independent role
for NUAK1 in RAPTOR regulation, and by phosphorylation of
MYPT1 by NUAK1, NUAK2 and potentially by additional ARKs.
Consistent with this, we also ﬁnd Ca2+-dependent phosphoryla-
tion of the canonical AMPK substrate ACC even after complete
suppression of CamKKβ-dependent AMPK activity in HeLa cells.
Clearly, considerably more work will be needed to disentangle
these complex signalling networks.
Whereas calcium has long been recognized to drive MYC
expression47 and more recently to regulate MYC function,48,49 the
reciprocal regulation of calcium signalling by MYC has not
garnered much attention. MYC was shown to increase calcium
signalling during B-cell differentiation by suppressing expression
of the calcium exporter PMCA.50 ChIP-SEQ analysis has revealed
MYC binding to the promoters of ITPR1-3, PRKCA and CamKK2 in
diverse cell types,30 consistent with our observation that MYC
promotes expression of these genes. The pronounced increase in
phosphorylation of the PKC substrate MARCKS compared with the
much more modest effect of MYC overexpression on PKCα levels
suggests that regulation of this pathway by MYC is only partially
explained by the observed transcriptional effects. Nevertheless,
our data do suggest that MYC actively selects for increased cellular
sensitivity to calcium, and does so in part to promote NUAK1
activity, maintain metabolic homoeostasis and thereby sustain cell
viability. The relative contribution of calcium signalling to NUAK1
activation likely depends on several factors including the strength
of calcium signalling, whether LKB1 is present or absent and, if
present, the relative levels of PKCα and LKB1 upstream.
MYC is a paradigm driver of apoptosis when expressed at high
levels51,52 whereas conventional PKC isoforms inhibit apoptosis in
many cell types.53 Suppression of PKCα or β induces
apoptosis,54–56 whereas overexpression has been shown to
suppress death induced by MYC or withdrawal of IL3.57,58 Both
PKCα and β isoforms have been shown to promote Ser473
phosphorylation of AKT,59,60 which inhibits canonical MYC-
induced apoptosis, primarily via suppression of pro-apoptotic
BH3 protein expression/function.61–63 Importantly, we showed
previously that MYC-overexpressing cells continue to require
NUAK1 even when active AKT is overexpressed,21 pointing to a
role for NUAK1 in protecting tumour cells from non-apoptotic cell
death and suggesting that calcium and PKCαmay govern multiple
pathways that promote tumour cell survival. Targeted suppression
of these pathways may thus have therapeutic beneﬁt in multiple
cancers where MYC is deregulated.64
MATERIALS AND METHODS
Cell culture
The identity of all cell lines was veriﬁed using an in-house cell line
validation service. HeLa and U2OS cells were maintained in
Dulbecco’s modiﬁed Eagles’s medium containing 4.5 g/l glucose,
1% glutamine, 100 U/ml of streptomycin, 100 U/ml of penicillin,
10% fetal bovine serum and incubated at 37 °C in 5% CO2. Primary
MEFs were isolated from mouse embryos (wild type; Rosa26-lsl-
Myc; Nuak1FL/FL) at E13.5 days and cultured as above except for
incubation in 3% oxygen. All cell lines were routinely tested for
mycoplasma contamination and were validated by STR proﬁling
using an approved in-house validation service (CRUK-BICR). Wild
type, Rosa26-lsl-MYC MEFs were infected with 300 multiplicity of
infection of Adeno-Cre replication-incompetent virus (University of
Iowa) to induce MYC expression. Nuak1FL/FL MEFs were infected
with retrovirus expressing tamoxifen-inducible Cre-ER and
selected on puromycin. SV40 T antigen-immortalized Prkaa1FL/FL;
Prkaa2FL/FL double ﬂoxed MEFs were generously provided by
Russell Jones, McGill University. For transient transfection, HeLa
cells were plated on 10 cm diameter dishes and transfected with
3 μg of DNA (FLAG-NUAK1wt, FLAG-NUAK1T211A or empty
vector) using Lipofectamine 3000 (Thermo Fisher, Waltham, MA,
USA) and lysed 48 h post-transfection. For protein translation
measurements, cells were cultured for with 30 μCi/ml 35S-
Methionine label (EasyTag from Perkin Elmer, Beaconsﬁeld, UK)
for 30 min and total protein was precipitated using a ﬁnal
concentration of 12.5% trichloroacetic acid. Scintillation (Ecoscint,
Thermo Fisher) was counted for 2 min.
Chemicals and antibodies
Phenformin, Sto-609, Rapamycin, phosphatase inhibitor cocktails
(P0044 and P5726), protease inhibitor cocktail (P8340) and MG132
were purchased from Sigma-Aldrich (Irvine, UK); HTH-01-015 from
Cambridge Bioscience (Cambridge, UK); A23187, Ionomycin and
A769662 from Abcam (Cambridge, UK); WZ4003, Gö6976 and
BAPTA-AM were purchased from Tocris (Bristol, UK). Antibodies
recognizing ACC phospho-Ser79(#3661), total ACC (#3676), Raptor
phospho-Ser792(#2083), total Raptor (#3661), AMPK phospho-
T172(#2535), total AMPK (#2532), total MYPT1 (#8574), PKCα
(#2056), NUAK1 (#4458), phospho-(Ser) PKC substrate (#2261),
MARCKS phospho-Ser159/163 (#11992) were purchased from Cell
Signalling Technologies (Danvers, MA, USA); anti-FLAG (#F1804),
anti-β-Actin (#A5441) were from Sigma-Aldrich; anti-MYPT1
phospho-Ser445(#S508C) and anti-NUAK2 (#S225B) were from
the MRC PPU, Dundee, UK; anti-MARCKS (#ab72459) anti-Histone
H2B (#ab1790), anti-Vinculin (#ab129002) and anti-c-Myc
(#ab32072) were purchased from Abcam. The phospho-T211
NUAK1 antibody was generated by Eurogentec (Liege, Belgium)
against the phosphopeptide KFLQTPO3FCGSPLY. The antibody was
afﬁnity puriﬁed from reactive serum using the same phosphor-
peptide after counter-selection with non-phosphorylated peptide.
In addition to the results shown, the antibody was further
validated by loss of signal upon siRNA-mediated depletion of
NUAK1. Secondary antibodies coupled to horseradish peroxidase
anti-mouse and anti-rabbit were purchased from GE Healthcare
(#NA931 and #NA934; Chicago, IL, USA), and anti-sheep was from
Pierce (#31480; Thermo Fisher).
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Figure 7. Diagram of calcium regulation of NUAK1, NUAK2
and AMPK.
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RNA interference
HeLa cells were passaged 12 h before transfection and transfected
at 70% conﬂuency using Lipofectamine RNAiMAX (Thermo Fisher)
with the following siRNA from Qiagen (Manchester, UK): non-
targeting control (1022076), NUAK1#1 (SI00108388), NUAK1#2
(SI00108388), PKCα#1 (SI00605934), PKCα#2 (SI00605927), NUAK2
(SI02660224), MYC#1 (SI00300902), MYC#2 (SI02662611), MYC#3
(SI03101847). shRNA against human MYC and a non-targeting
control (Renilla) were designed by and purchased from Mirimus Inc.
(Woodbury, NY, USA): ShMYC1702—CGCCTCCCTCCACTCGGAAGGA;
shMYC1891—CTGAGTCTTGAGACTGAAAGAT. HeLa cells were trans-
fected with 3 μg of shRNA-encoding plasmid using Lipofectamine
3000. After transfection, cells were treated and analysed as for ﬁgure
legends.
Quantitative real-time PCR
RNA was isolated by Trizol and was reversed transcribed using
QuantiTect Reverse Transcription Kit (Qiagen), according to the
manufacturer’s instructions. Real-time quantiﬁcation was per-
formed using SYBR Green Fast Mix (VWR, Lutterworth, UK) with
C1000 thermal cycler (Bio-Rad, Watford, UK). Primers for NUAK1
(forward, 5’-ccgctcactgatgtaatcgt; reverse, 5’-gtcatctctcaaccatcct-
cat), ACTIN (forward, 5’-ccaaccgcgagaagatga; reverse, 5’-ccaga
ggcgtacagggatag) ITPR1 (forward, 5′-GAAGGCATCTTTGGAGG
AAGT-3′; reverse, 5′-ACCCTGAGGA-AGGTTCTG-3′), PKCα (forward,
5′-CAAGGGATGAAATGTGACACC-3′; reverse, 5′-CCTCTTCT-CTGTG
TGATCCATTC-3′), CaMKKβ (forward, 5′-GGAGGTCGAGAACTC
AGTCAA; reverse, 5′-CATGGTCTTCACCAGGATCA) and β2m (for-
ward, 5′-ACCTCCATGATGCTGCTTAC-3′; reverse, 5′-GGACTGGTC
TTTCTATCTCTTGTAC-3′) were obtained from IDT (Leuven, Belgium).
Immunoprecipitation and immunoblotting
FLAG-NUAK1 wild type, mutant (T211A) or empty vector
transiently overexpressed HeLa cells were rinsed with ice-cold
phosphate-buffered saline and then lysed in Lysis Buffer contain-
ing 50 mM Tris-HCl (pH 7.5), 1% NP-40, 0.27 M sucrose and
phosphatase/protease inhibitors. Cell lysates (1 mg) were incu-
bated overnight at 4 °C with anti-FLAG M2 Afﬁnity gel (Sigma,
Irvine, UK; A2220). Immunoprecipitated were washed twice with
Lysis Buffer containing 0.15 M NaCl, twice with 50 mM Tris-HCl (pH
7.5) plus phosphatase inhibitors and resuspended in sodium
dodecyl sulphate sample buffer. For whole-cell extracts, cells were
rinsed with ice-cold phosphate-buffered saline and then lysed
in situ with lysis buffer containing 150 mM NaCl, 50 mM Tris (pH
7.5), 1% NP-40, 0.5% sodium deoxycholic acid, 1% sodium dodecyl
sulphate plus protease and phosphatase inhibitor cocktails.
Lysates were then sonicated to reduce viscosity and diluted in
sodium dodecyl sulphate sample buffer. Immunoprecipitated and
whole-cell extracts were resolved by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis, transferred to nitrocellulose
membranes for subsequent incubation with primary antibodies
overnight at 4 °C. Densitometry analysis of individual immuno-
blots was performed using ImageJ (NIH, Bethesda, MD, USA).
Cell death analysis
HeLa cells were treated or transfected as for ﬁgure legends and on
the day of the analysis the supernatant was collected, cells were
rinsed in phosphate-buffered saline and harvested by trypsinization.
Cells were then centrifuged at 300 g for 5 min at 4 °C and pellet
incubated in 200 μl Annexin V binding buffer (10 mM HEPES pH 7.4,
140 mM NaCl, 2.5 mM CaCl2) containing APC-Annexin V (Biolegend,
San Diego, CA, USA) for 10 min at room temperature. Propidium
iodide was added prior to analysis by FACSCalibur (BD Biosciences,
Wokingham, UK) ﬂow cytometry.
Statistical analysis
Raw data were uploaded into Prism (Graphpad, La Jolla, CA, USA)
or Excel (Microsoft, Reading, UK) spreadsheets for generation of
graphs. All experiments were performed on at least three
occasions, except where noted, and mean and s.d. values from
biological replicates are presented. Statistical signiﬁcance was
determined by T-test and one-way or two-way ANOVA as per
ﬁgure legends. * denotes Po0.05; **o0.01; ***o0.001.
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